Serum periostin during omalizumab therapy in asthma: a tool for patient selection and treatment evaluation

Omalizumab is an effective treatment for severe allergic asthma.1 Nevertheless, even in patients meeting the prescription criteria, lack of efficacy has been described as the most common reason for treatment discontinuation, at least in the real-life setting.2 An association between baseline serum periostin (SP) levels, evaluated before the start of treatment, and omalizumab efficacy has been recently described,3,4 suggesting the relevance of this molecule as a biomarker for patient selection and predictor of treatment response.

http://ift.tt/2wyQHAf